


# Product Data Sheet

## Verteporfin

<b>Cat. No.:</b>	A8327
<b>CAS No.:</b>	129497-78-5
<b>Formula:</b>	C <sub>41</sub> H <sub>42</sub> N <sub>4</sub> O <sub>8</sub>
<b>M.Wt:</b>	718.79
<b>Synonyms:</b>	CL 318952; Visudyne
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	Store at -20°C



## Solvent & Solubility

≥ 18.3mg/mL in DMSO

In Vitro

Preparing Stock Solutions	Solvent Concentration	Mass		
		1mg	5mg	10mg
	1 mM	1.3912 mL	6.9561 mL	13.9123 mL
	5 mM	0.2782 mL	1.3912 mL	2.7825 mL
	10 mM	0.1391 mL	0.6956 mL	1.3912 mL

Please refer to the solubility information to select the appropriate solvent.

## Biological Activity

Shortsummary

Photosensitizer used in photodynamic therapy

IC<sub>50</sub> & Target

In Vitro

### Cell Viability Assay

Cell Line:	HL-60 cells
Preparation method:	The solubility of this compound in DMSO is > 18.3 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.
Reacting conditions:	0 ~ 100 ng/mL; 60 mins
Applications:	Verteporfin at 50 ng/mL caused DNA fragmentation in 25% of irradiated cells.

	At lower concentrations of the photosensitizer, few (~ 5%) cells exhibited a hypodiploid amount of DNA. According to MTT assays performed 24 hrs after irradiation, there was an 85% or greater loss in viability for cells treated with Verteporfin at $\geq 25$ ng/mL. Light or Verteporfin alone did not result in DNA fragmentation or affect cell viability.	
In Vivo	<b>Animal experiment</b>	
	Animal models:	NOG mice bearing PhLO cells
	Dosage form:	140 mg/kg/day; s.c.; from days 22 to 28
	Applications:	In NOG mice bearing PhLO cells, Verteporfin alone significantly reduced the leukemia cell ratio. The combination of Verteporfin and Dasatinib further reduced the number of leukemia cells in the spleen. In addition, there was no significant body weight loss in any group, which suggested that erteporfin and Dasatinib alone or in combination did not exhibited obvious drug toxicity.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

## Product Citations

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References


- [1]. Granville DJ, Carthy CM, Jiang H, et al. Nuclear factor-kappa B activation by the photochemotherapeutic agent verteporfin. *Blood*, 2000, 95(1): 256-262.
- [2]. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. *Survey Of Ophthalmology*, 2000, 45(3): 195-214.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

*Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.*



**APEX BIO Technology**

[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

